Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

Diabetes Care

Volumn 24, Issue 3, 2001, Pages 489-494

  Mannucci, Edoardo ^a   Ognibene, Agostino ^b   Cremasco, Francesco ^a   Bardini, Gianluca ^a   Mencucci, Antonella ^a   Pierazzuoli, Enrica ^a   Ciani, Silvia ^a   Messeri, Gianni ^b   Rotella, Carlo M ^a,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c Insegnamento di Malattie Metaboliche e del Ricambio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN; LEPTIN; METFORMIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE TOLERANCE TEST; HORMONE BLOOD LEVEL; HUMAN; MALE; OBESITY; PLASMA; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0035097211     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.3.489     Document Type: Article

References (25)

1. Worldwide experience of metformin as a glucoselowering agent: A meta-analysis
2. Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese Zucker rats
3. Biguanides and NIDDM
4. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
5. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus
6. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes
7. Effect of metformin on food intake in obese subjects
8. Glucagon-like peptide-1: A potent regulator of food intake in humans
9. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men
10. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide 1
11. Glucagon-like peptide-1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment
12. Human studies with glucagon-like peptide-1: Potential of the gut hormone for clinical use
13. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
14. The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects
15. Effects of metformin on intestinal and pancreatic endocrine secretion in type 2 (non-insulin-dependent) diabetes
16. Hyperglycaemia but not hyperinsulinaemia prevents the secretion of glucagon-like peptide-1 (7-36 amide)
17. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients
18. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans
19. Relationship between leptin and oestrogens in healthy women
20. Glucose clamp technique: A method for quantifying insulin secretion and resistance
21. 2-terminus in type II diabetic patients and in healthy subjects
22. Elevation of plasma leptin concentrations in obese hyperinsulinemic hypothyroidism before and after treatment
23. Interaction of insulin, glucagon-like peptide-1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate
24. Preclinical pharmacology of biguanides
25. Glucagon-like peptide-1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal